knowledge -WSS

knowledge

author：leisure time 2025-10-02 21:00:28 - browse：6796

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Stop Congress from blocking public access to science

knowledge

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

How dance can help health care workers heal from trauma

Stanford president to resign after investigation of research

What we owe ALS patients — and why one company fell short

DOJ, FTC to increase scrutiny of all types of health care mergers

The Karikó problem: Lessons for funding basic research

knowledge

knowledge

leisure time

Psychedelics group wrestles with new pharma identity

The kidney, in all its complexity, is captured in a new atlas

Heart attack and stroke risk calculators need revising

TikTok cracks down on users posting about weight loss drugs

Novavax promises a turnaround & Lilly roils the obesity market

IVG is promising — but it won’t replace IVF quite yet

Affirmative action in medical school literally saved lives

Health insurers' Q3 question: how much care are people getting?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Will an HIV vaccine ever be a reality?

leisure time

The United States is paying nearly triple for new Covid vaccines

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Some top drug companies are starting to take action on climate

Researchers separate signal from noise in heart wearable data

Medicare innovation center doesn’t save money, experts say

entertainment

leisure time

knowledge

focus